BE851447A - 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique - Google Patents

2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique

Info

Publication number
BE851447A
BE851447A BE174951A BE174951A BE851447A BE 851447 A BE851447 A BE 851447A BE 174951 A BE174951 A BE 174951A BE 174951 A BE174951 A BE 174951A BE 851447 A BE851447 A BE 851447A
Authority
BE
Belgium
Prior art keywords
dimethoxyquinazolines
piperazinyl
pharmacological application
pharmacological
application
Prior art date
Application number
BE174951A
Other languages
English (en)
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of BE851447A publication Critical patent/BE851447A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE174951A 1976-02-18 1977-02-15 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique BE851447A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/659,059 US4060615A (en) 1976-02-18 1976-02-18 2-Piperazinyl-6,7-dimethoxyquinazolines

Publications (1)

Publication Number Publication Date
BE851447A true BE851447A (fr) 1977-08-16

Family

ID=24643862

Family Applications (1)

Application Number Title Priority Date Filing Date
BE174951A BE851447A (fr) 1976-02-18 1977-02-15 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique

Country Status (22)

Country Link
US (1) US4060615A (fr)
JP (1) JPS52100479A (fr)
AU (1) AU505080B2 (fr)
BE (1) BE851447A (fr)
CA (1) CA1090803A (fr)
CH (2) CH620925A5 (fr)
CY (1) CY1155A (fr)
DE (1) DE2707068A1 (fr)
DK (1) DK144010C (fr)
FI (1) FI64586C (fr)
FR (1) FR2341576A1 (fr)
GB (1) GB1545697A (fr)
HK (1) HK32682A (fr)
IE (1) IE44613B1 (fr)
KE (1) KE3221A (fr)
LU (1) LU76779A1 (fr)
MY (1) MY8300172A (fr)
NL (1) NL7701584A (fr)
SE (1) SE431753B (fr)
SG (1) SG30882G (fr)
YU (4) YU42577A (fr)
ZA (1) ZA77587B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
JPS6016948B2 (ja) * 1978-03-29 1985-04-30 住友化学工業株式会社 新規なキナゾリン誘導体及びその製造法
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0022481A1 (fr) * 1979-06-21 1981-01-21 Mitsubishi Yuka Pharmaceutical Co., Ltd. Dérivés de la 5,6-alcoylènepyrimidine, procédés pour leur préparation et préparations pharmaceutiques
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
DE3304292A1 (de) * 1982-10-11 1984-04-12 Brown, Boveri & Cie Ag, 6800 Mannheim Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock
DE3346675A1 (de) * 1983-12-23 1985-07-04 Beiersdorf Ag, 2000 Hamburg Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte
AT384218B (de) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Verfahren zur herstellung von neuen chinazolin-derivaten
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
CA2077252C (fr) * 1992-08-31 2001-04-10 Khashayar Karimian Methodes de fabrication d'urees et de guanidines et composes intermediaires servant a ces syntheses
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
CA2238283C (fr) 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
EP2295436A1 (fr) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phényl-substitués Imidazotriatinone comme inhibiteurs de la phosphodiesterase V
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
EP1364950A4 (fr) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Derive de pyridopyrimidine ou naphthyridine
CA2449163C (fr) * 2001-05-09 2010-07-13 Bayer Healthcare Ag Utilisation nouvelle d'imidazotriazinones 2-phenyl-substituees
EP1312363A1 (fr) * 2001-09-28 2003-05-21 Pfizer Products Inc. Méthode de traitement et kit comprenant un secrétagogue d'hormone de croissance
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
MXPA04009996A (es) * 2002-04-12 2005-07-01 Celgene Corp Metodos para la identificacion de moduladores de la angiogenesis, compuestos descubiertos por los mismos, y metodos de tratamiento usando los compuestos.
WO2003087333A2 (fr) * 2002-04-12 2003-10-23 Celgene Corporation Modulation de differenciation de cellule souche et de cellule progenitrice, analyses et utilisations associees
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
CN102786482A (zh) 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
EP2054418B1 (fr) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothiéno pyrimidines comme inhibiteurs de la protéine kinase akt
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
KR20150091196A (ko) * 2007-07-05 2015-08-07 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP5539225B2 (ja) * 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
WO2009089459A1 (fr) * 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
EP2694072B1 (fr) 2011-04-01 2017-11-29 Genentech, Inc. Combinaison de composé inhibiteur d'akt et d'abiraterone pour utilisation dans des traitements thérapeutiques
MX2013011333A (es) 2011-04-01 2014-04-16 Genentech Inc Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
US11944624B2 (en) * 2017-07-06 2024-04-02 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
JPS4966691A (fr) * 1972-10-30 1974-06-27
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives

Also Published As

Publication number Publication date
AU505080B2 (en) 1979-11-08
DK144010B (da) 1981-11-16
FI64586C (fi) 1983-12-12
YU40622B (en) 1986-02-28
CA1090803A (fr) 1980-12-02
CH623051A5 (fr) 1981-05-15
CY1155A (en) 1983-01-28
SG30882G (en) 1983-07-08
DK65077A (da) 1977-08-19
US4060615A (en) 1977-11-29
ZA77587B (en) 1977-12-28
YU165482A (en) 1982-10-31
AU2189777A (en) 1978-08-10
FI64586B (fi) 1983-08-31
SE7701731L (sv) 1977-08-19
IE44613B1 (en) 1982-01-27
YU42577A (en) 1982-10-31
FR2341576B1 (fr) 1979-01-19
HK32682A (en) 1982-07-23
KE3221A (en) 1982-08-13
NL7701584A (nl) 1977-08-22
SE431753B (sv) 1984-02-27
JPS52100479A (en) 1977-08-23
DE2707068A1 (de) 1977-09-01
YU165382A (en) 1982-10-31
GB1545697A (en) 1979-05-10
FR2341576A1 (fr) 1977-09-16
IE44613L (en) 1977-08-18
CH620925A5 (fr) 1980-12-31
YU165282A (en) 1982-10-31
FI770486A (fr) 1977-08-19
DK144010C (da) 1982-04-26
LU76779A1 (fr) 1977-08-19
MY8300172A (en) 1983-12-31

Similar Documents

Publication Publication Date Title
BE851447A (fr) 2-piperazinyl-6,7-dimethoxyquinazolines et leur application pharmacologique
BE859012A (fr) Derives de 4-n-acylfortimicines b, leur preparation et leur application
NL7713141A (nl) Scheidingssamenstel.
IT1083937B (it) Ombrello
FI781386A (fi) Farmakologiskt aktiva komponenter
SE7608748L (sv) Acyl-sackariner och acyl-3-oxo-1,2-bensisotiazoliner
FR2343870A2 (fr) Structure de mur-rideau
FI781490A (fi) Farmakologiskt aktiva komponenter
BE860736A (fr) Derives de piperidine et leur preparation.
BE847396A (fr) Alkoxysilanes et leur preparation,
BE871702A (fr) Isochromanes, isothiochromanes, 2-benzoxepines et 2-benzothiepines
BE855471A (fr) Nonapeptides nouveaux et leur preparation
BE853027A (fr) Nouvelles n-oxy-amidino-urees
BE871807A (fr) 4-quinolyl-guanidines, leur preparation et leur utilisation
BE859987A (fr) Nouvelles aza-8 purinones-6
DK259777A (da) Paraply
FR2342290A1 (fr) Aminoalkylpyrrolobenzoxo-aza-alcanes, leur preparation et leurs applications
FR2545826B1 (fr) Dihydropyridylimidates cycliques, et leur application pharmacologique
BE859221A (fr) Bis-carbamoylsulfures n-substitues et leur preparation
BE869352A (fr) Nouvelles nitrosourees et leur application
BE853203A (fr) Antibiotiques anti-tumerus ma 144-m1 et ma 144-m2
BE858682A (fr) Nouvelles 11-deoxy-11-oxaprostaglandines
DK408577A (da) Indgivelsessaet
NL7808443A (nl) Arylfosfonieten en arylthiofosfonieten.
NL7801927A (nl) Gesubstitueerde pyrrolochinoxalinonen en pyrrolobenzodiazepinonen.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BRISTOL-MYERS CY

Effective date: 19850215